CASPER MARC N 4
4 · THERMO FISHER SCIENTIFIC INC. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Thermo Fisher (TMO) CEO Marc N. Casper Exercises Options, Sells 4,000 Shares
What Happened
- Marc N. Casper, Chairman & CEO (also a director) of Thermo Fisher Scientific (TMO), exercised 4,000 stock options on March 5, 2026 (exercise price $309.63; cash paid $1,238,520) and sold 4,000 shares in multiple open-market transactions the same day for aggregate proceeds of $2,059,261 (approx. $514.82/share average). The Form 4 also reports a related derivative disposition of 4,000 shares at $0.00 (reported as a derivative transaction).
- These actions are reporting sales (S) and option exercises (M); selling the shares after exercising is common and does not necessarily indicate a change in view on the company.
Key Details
- Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely).
- Exercise: 4,000 shares acquired at $309.63 each (total $1,238,520).
- Sales: 4,000 shares sold across multiple trades for total proceeds $2,059,261 (weighted-average ≈ $514.82/share); individual sale price ranges are provided in the filing footnotes (see below).
- Shares owned after transaction: Not specified in the summarized data on this notice.
- Notable footnotes: Transactions were effected under a Rule 10b5-1 trading plan adopted November 11, 2025 (F1). Several weighted-average price footnotes list the price ranges for groups of trades (F2–F13). The filing also includes disclaimers regarding indirect beneficial ownership (F14, F15).
- Transaction codes: M = option exercise/convert; S = open-market sale.
Context
- This appears to be a routine exercise-and-sell sequence (exercise of vested options followed by market sales). The filing shows the option exercise and same-day sales; one line reports a derivative disposition at $0.00 consistent with option conversion/settlement reporting practices.
- Because the trades were made under a pre-existing Rule 10b5-1 plan, the trades were preauthorized and executed according to the plan’s terms (which can limit inference about timing or intent).
Insider Transaction Report
Form 4
CASPER MARC N
DirectorChairman & CEO
Transactions
- Exercise/Conversion
Common Stock
2026-03-05$309.63/sh+4,000$1,238,520→ 127,925.358 total - Sale
Common Stock
[F1]2026-03-05$503.66/sh−20$10,073→ 127,905.358 total - Sale
Common Stock
[F1][F2]2026-03-05$505.76/sh−60$30,346→ 127,845.358 total - Sale
Common Stock
[F1][F3]2026-03-05$507.54/sh−58$29,437→ 127,787.358 total - Sale
Common Stock
[F1][F4]2026-03-05$509.66/sh−99$50,456→ 127,688.358 total - Sale
Common Stock
[F1][F5]2026-03-05$511.78/sh−214$109,521→ 127,474.358 total - Sale
Common Stock
[F1][F6]2026-03-05$512.73/sh−411$210,732→ 127,063.358 total - Sale
Common Stock
[F1][F7]2026-03-05$513.71/sh−1,133$582,033→ 125,930.358 total - Sale
Common Stock
[F1][F8]2026-03-05$514.71/sh−570$293,385→ 125,360.358 total - Sale
Common Stock
[F1][F9]2026-03-05$515.64/sh−348$179,443→ 125,012.358 total - Sale
Common Stock
[F1][F10]2026-03-05$516.73/sh−201$103,863→ 124,811.358 total - Sale
Common Stock
[F1][F11]2026-03-05$517.83/sh−106$54,890→ 124,705.358 total - Sale
Common Stock
[F1][F12]2026-03-05$519.13/sh−516$267,871→ 124,189.358 total - Sale
Common Stock
[F1][F13]2026-03-05$519.74/sh−264$137,211→ 123,925.358 total - Exercise/Conversion
Stock Option (Right to Buy)
[F16]2026-03-05−4,000→ 40,550 totalExercise: $309.63Exp: 2027-02-25→ Common Stock (4,000 underlying)
Holdings
- 11,300(indirect: By Trust)
Common Stock
[F14] - 14,608(indirect: By Floral Park Associates, Inc.)
Common Stock
- 5,000(indirect: By Trust)
Common Stock
[F15]
Footnotes (16)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.47 to $517.07, inclusive.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.60 to $518.16, inclusive.
- [F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.62 to $519.57, inclusive.
- [F13]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.62 to $519.91, inclusive.
- [F14]The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
- [F15]The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
- [F16]The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.36 to $506.16, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $507.40 to $508.12, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.63 to $509.76, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.21 to $512.18, inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.23 to $513.22, inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.27 to $514.24, inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.28 to $515.24, inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.30 to $516.00, inclusive.
Signature
/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper|2026-03-09